Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTER, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company has changed the timing of its previously announced first quarter 2023 financial results webcast and conference call to 5:30 p.m. Eastern Time on Wednesday, May 10, 2023.

Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/tquygjuv. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIaab243465e1942deb84daf92e4eb35d8. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

CONTACT: Investor Contacts 
Matt Lowell 
Chief Financial Officer 
matt.lowell@teknova.com
+1 831-637-1100 

Sara Michelmore 
MacDougall Advisors 
smichelmore@macdougall.bio 
+1 781-235-3060 

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
jenn.henry@teknova.com  
+1 831-313-1259 

Staff

Recent Posts

AdvancedPCB Appoints Gary Stoffer as Chief Commercial Officer

AURORA, Colo. , April 16, 2025 /PRNewswire/ -- AdvancedPCB is proud to announce the appointment of…

4 hours ago

Two New Research Chairs in Microbiology at INRS

MONTREAL, April 16, 2025 /CNW/ - Professors Eric Déziel and Étienne Yergeau are leading two new…

4 hours ago

Findhelp Chosen by the Minnesota Department of Human Services to Launch Statewide Behavioral Health Program Locator

Innovative platform to streamline crisis response, connect individuals to care, and provide real-time behavioral health…

4 hours ago

New ICD-10 Codes Recognize Fontan-Associated Conditions, Advancing Care and Coverage for Rare Congenital Heart Disease Community

SEOUL, South Korea, April 16, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, a global leader in the development…

4 hours ago

Perspire Sauna Studio Strengthens California Roots with New Deal Signing in San Jose

Nation's Leading Infrared and Red-Light Sauna Franchise to Debut in Almaden in Spring 2026 SAN…

4 hours ago

Clario Collaborates with AWS to Push New Boundaries in Clinical Data Analysis with Generative AI

Clario's Advanced AI-Powered Platform Streamlines Clinical Document Processing to Facilitate Faster Drug Development Timelines PHILADELPHIA,…

4 hours ago